PharmaCyte Biotech Debt to Equity

PharmaCyte Biotech's debt-to-equity ratio stands at 0.0. That is below the Healthcare sector average of 0.3. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

PharmaCyte Biotech sits lower the Healthcare benchmark (0.3) with a debt-to-equity ratio of 0.0. That is roughly 100.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 0.0 is attractive depends on PharmaCyte Biotech's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how PharmaCyte Biotech's debt-to-equity ratio evolved across reporting periods, while the comparison chart places PMCB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, debt-to-equity ratio is commonly used to spot outliers. PharmaCyte Biotech's reading of 0.0 (sector avg 0.3) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.